

Curriculum vitae

Mirjam Stahl, M.D.

Date of birth: October 30, 1983

Place of birth: Bendorf, Germany

Nationality: German

Current Positions

W2 Heisenberg Professorship for Translational Pediatric Pulmonology (funded by the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG)) at the Charité - Universitätsmedizin Berlin

Head of the Division of Cystic Fibrosis (CF) at the Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine of the Charité – Universitätsmedizin Berlin

Consultant Physician (Oberärztin) at the Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine of the Charité – Universitätsmedizin Berlin

Group Leader of the Research Group „Risk Factors and Therapy of Early CF Lung Disease“
Associated Principal Investigator of the German Center for Lung Research (Deutsches Zentrum für Lungenforschung, DZL)

Advanced Clinician Scientist at the Berlin Institute of Health (BIH)

Affiliation

Charité - Universitätsmedizin Berlin – Campus Virchow Klinikum
Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine
Division of Cystic Fibrosis
Augustenburger Platz 1
D-13353 Berlin
Germany

Phone: +49 30 450 616408

Fax: +49 30 450 566931

Email: mirjam.stahl@charite.de

Scientific Vita

- | | |
|---------|--|
| 2025 | Early tenure for the W2 Professorship associated with the DFG Heisenberg Professorship at the Charité – Universitätsmedizin Berlin |
| 2024 | Call for the W3 Professorship of Pediatrics, University Heidelberg/Mannheim, Germany |
| 2022 | Call for the W2 Professorship associated with the DFG Heisenberg Professorship at the Charité – Universitätsmedizin Berlin |
| 2021 | Call for the W2 Professorship "Pediatric Pulmonology and Allergology" at the University of Lübeck, Germany |
| 2021 | Admission to the Heisenberg program of the DFG (W2 Heisenberg Professorship for Translational Pediatric Pulmonology) |
| 2021 | Admission to the Berlin Institute of Health (BIH) clinician scientist program as an advanced clinician scientist |
| 03/2020 | <i>Venia legendi</i> for Pediatrics, Medical Faculty, Charité - Universitätsmedizin Berlin (habilitation recognition procedure) |

- 2020-present Head of Division of CF, Consultant Physician (Oberärztin) and Group Leader of the Research Group „Risk Factors and Therapy of Early CF Lung Disease“, Department of Pediatric Respiratory Medicine, Immunology and Intensive Care Medicine, Charité - Universitätsmedizin Berlin (Director: Prof. Dr. M. A. Mall)
- 09/2019 Habilitation and *venia legendi* for Pediatrics, Medical Faculty, University of Heidelberg. Title of habilitation thesis: “Investigations on onset and early progression of lung disease in cystic fibrosis (Untersuchungen zur Entstehung und frühen Progression der Lungenerkrankung bei Mukoviszidose)”
- 2018-2019 Consultant Physician (Oberärztin), Division of Pediatric Pulmonology & Allergy and Cystic Fibrosis Center, Department of Pediatrics, University Hospital Heidelberg (Director: Prof. Dr. A. E. Kulozik)
- 2017-2019 Group Leader of Junior Research Group „Early CF Lung Disease“ (funded by Federal Ministry of Education and Research (Bundesministerium für Bildung und Forschung (BMBF)/DZL), Translational Lung Research Center Heidelberg (TLRC), University of Heidelberg
- 2014-present Principal Investigator of the DZL
- 2014-2018 Clinical and Research Fellow in Pediatric Pulmonology and Allergy, Division of Pediatric Pulmonology & Allergy and Cystic Fibrosis Center, Department of Pediatrics, Pediatric Clinic III (Director: Prof. Dr. A. E. Kulozik) and Department of Translational Pulmonology, TLRC Heidelberg, University of Heidelberg (Director: Prof. Dr. M. A. Mall)
- 02/2014 Dissertation (M.D.) with honors (*summa cum laude*), Albert-Ludwigs-University of Freiburg
- 2009-2014 Resident in Pediatrics and Research Fellow, Department of Pediatrics, University Hospital Heidelberg (Director of Pediatric Clinic I: Prof. Dr. G. Hoffmann, Director of Pediatric Clinic III: Prof. Dr. A. E. Kulozik)
- 2005-2007 Experimental Doctoral Thesis, Department of Pulmonology, Albert-Ludwigs-University of Freiburg. Title: „Die Bedeutung des Scavengerrezeptors Klasse A Typ I (CD204) als Kollagenrezeptor der Alveolarmakrophagen“ (Thesis supervisor: Prof. Dr. J. Müller-Quernheim)
- 2004–2008 Medical School, Albert-Ludwigs-University of Freiburg, Germany (final grade in the state examination: 1.5)
- 2002–2004 Medical School at the University of Rostock, Germany
- 03/2002 A levels passed as head of the class, Schönstätter Marienschule, Vallendar, Germany

Clinical Qualifications

- 2018 Board certification in Allergy
- 2017 Board certification in Pediatric Pulmonology
- 2015 Board certification in Pediatrics

Other Professional Activities and Qualifications

- 2025-present Elected member of the federal executive committee of Mukoviszidose e.V.
- 2025-present Elected President Elect of the German Society of Pediatric Pulmonology (Gesellschaft für Pädiatrische Pneumologie, GPP)
- 2024-present Member of the Leading Committee of the American Thoracic Society (ATS) task force Multiple-breath washout (MBW) Standard Update
- 2021-2025 Elected treasurer of the German Society of Pediatric Pulmonology (Gesellschaft für Pädiatrische Pneumologie, GPP)

- 2020-present Elected chairman of the board of the research council of the German CF association (Forschungsgemeinschaft Mukoviszidose, FGM)
- 2020-present Member of the European Respiratory Society (ERS) task force Multiple-breath washout (MBW) Global Lung Function Initiative (GLI)
- 2020-2023 Elected Secretary of Group 07.03 "Pediatric cystic fibrosis" of Assembly 7 within the ERS
- 2019 Member of the Steering Committee of the TLRC Heidelberg, Partner Site of the DZL
- 2019 Baden-Württemberg Certification for University Didactics
- 2018-2020 Elected member of the board of the research council of the FGM
- 2018 Course on education and training (DOS) III, University Heidelberg
- 2016-present Certified MBW operator for clinical trials in adults and children, European Cystic Fibrosis Society-Clinical Trial Network (ECFS-CTN)
- 2015 DOS I & II, University Heidelberg
- 2011 Certificate as trainer for asthmatic children
- 2010 GCP training course for clinical trial investigators, KKS Mainz (ongoing participation in refresher courses)

Activities in the Field of Academic Self-governance

- 2022-present Member of various appointment committees of the Charité – Universitätsmedizin Berlin
- 2012-2017 Pediatric residents' representative (Assistentensprecherin), Department of Pediatrics, University Hospital Heidelberg

Activities in Teaching and Mentoring

- 2023-present Mentor of Dr. Ruth Maria Urbantat within BIH Junior Clinician Scientist Program
- 2022-present Mentor of Dr. Eva Steinke within BIH Junior Clinician Scientist Program
- 2020-present Supervisor of fifteen medical doctoral candidates (4 finished, 2 writing final document for submission to faculty, 3 performing final analysis, 7 ongoing)
- 2020-present Participation in diverse teaching formats within the medical studies program of the Charité – Universitätsmedizin Berlin
- 2016-2021 Co-supervisor of medical doctoral candidate Eva Steinke (doctorate completed)
- 2009-2019 Participation in diverse teaching formats within the medical studies program of the University Heidelberg

Organisation of Academic Events

- Since 2024 Member of the Scientific Committee of the European Cystic Fibrosis Society (ECFS) organizing the annual conference (ECFC)
- 2021 Organizing chair of the annual German cystic fibrosis conference, 19th – 20th November 2021, online
- 2019 Organizing chair of the 19th Scientific Meeting of the Scientific advisory board of the German Research Community for Cystic Fibrosis (FGM) "Future medicine in CF", 19th – 20th September 2019, Schloss Montabaur, Germany

Editor Assignments (Peer Review Journals)

European Respiratory Review

Reviewer Assignments (Peer Review Journals)

Ad hoc review (selection): *American Journal of Respiratory and Critical Care Medicine*, *BioMed Central Pulmonary Medicine*, *Cells*, *European Journal of Pediatrics*, *European Respiratory Journal* (Top Reviewer 2023), *European Respiratory Journal Open Research*, *Journal of Applied Physiology*, *Journal of Bone and Mineral Research*, *Journal of Cystic Fibrosis* (Top Reviewer 2020), *Journal of Magnetic Resonance Imaging*, *Klinische Pädiatrie*, *Molecular and Cellular Pediatrics*, *Pediatric Pulmonology*, *PLoS One*, *Respiration*, *Respiratory Medicine*, *Scientific Reports*, *Swiss Medical Weekly*, *Thorax*

Memberships in Professional Societies

2020-present American Thoracic Society (ATS)
2017-present German Society of Pulmonology (DGP)
2013-present European Respiratory Society (ERS)
2012-present German Cystic Fibrosis Association (Mukoviszidose e.V.)
2011-present European Cystic Fibrosis Society (ECFS)
2010-present German Society of Pediatric Pulmonology (GPP)
2010-present German Society of Pediatric Allergy (GPA)
2010-present German Society of Pediatrics and Adolescent Medicine (DGKJ)

Extramural Funding

Research Grants as PI

2022-2027 W2 Heisenberg Professorship for Translational Pediatric Pulmonology, German Research Foundation (Deutsche Forschungsgemeinschaft, DFG)
2022-2025 Independent CF Research Innovation Award with research program “Characterization of Risk Factors for Progression in Early Cystic Fibrosis Lung Disease”, Vertex Pharmaceuticals; Amount: 750.000USD; Role: PI
2019-2022 DZL 2.0 Clinical Study “Inhibition of Interleukin-1 Receptor with Anakinra as a Novel Anti-inflammatory Strategy for Cystic Fibrosis Lung Disease”, DZL, BMBF; Amount: 100.000€; Role: PI for central MBW analysis
2018-2021 Multicenter trial VX16-809-121 for Vertex Pharmaceuticals; Amount: 100.000€; Role: central MBW overreader
2017-2019 DZL Junior Research Group “Early CF Lung Disease”, DZL, BMBF; Amount: 590.000€; Role: Group Leader
2017 Christiane Herzog Research Award for the longitudinal investigation of CF lung disease in childhood using MBW, Christiane Herzog Foundation; Amount: 50.000€; Role: PI
2016 DZL 2.0 Funding for Preparation of a Clinical Trial: “Inhibition of Interleukin-1 Receptor with Anakinra as a Novel Anti-inflammatory Strategy for Cystic Fibrosis Lung Disease”, DZL, BMBF; Amount: 15.000€; Role: PI for central MBW analysis
2015-2017 Clinician Scientist Career Development Award, Mukoviszidose e.V.; Amount: 84.000€; Role: Recipient
2013-2015 DZL 1.0 Clinical Study “Preventive Inhaled Hypertonic Saline in Cystic Fibrosis (PRESIS)”, DZL, BMBF; Amount: 200.000€; Role: PI for central MBW analysis
2011-2015 Pilot Study on Safety and Efficacy of Preventive Inhalation with Hypertonic Saline in Infants with Cystic Fibrosis, Dietmar Hopp Foundation; Amount: 190.000€; Role: PI for central MBW analysis

Research Grants as Co-PI

- 2019-2022 DZL 2.0 Clinical Study "Inhibition of Interleukin-1 Receptor with Anakinra as a Novel Anti-inflammatory Strategy for Cystic Fibrosis Lung Disease", DZL, BMBF; Amount: 600.000€; Role: Co-PI
- 2016 DZL 2.0 Funding for Preparation of a Clinical Trial: "Inhibition of Interleukin-1 Receptor with Anakinra as a Novel Anti-inflammatory Strategy for Cystic Fibrosis Lung Disease", DZL, BMBF; Amount: 30.000€; Role: Co-PI
- 2013-2015 DZL 1.0 Clinical Study "Preventive Inhaled Hypertonic Saline in Cystic Fibrosis (PRESIS)", DZL, BMBF; Amount: 430.000€; Role: Co-PI
- 2011-2015 Pilot Study on Safety and Efficacy of Preventive Inhalation with Hypertonic Saline in Infants with Cystic Fibrosis, Dietmar Hopp Foundation; Amount: 380.000€; Role: Co-PI

Travel Grants

- 2018 North American Cystic Fibrosis Conference (NACFC), Denver, Colorado, USA; Mukoviszidose e.V.
- 2017 NACFC, Indianapolis, Indiana, USA; Mukoviszidose e.V.
- 2016 ERS, London, UK; Mukoviszidose e.V.
- 2015 NACFC, Phoenix, Arizona, USA; Cystic Fibrosis Foundation (CFF)
- 2013 NACFC, Salt Lake City, Utah, USA; Mukoviszidose e.V.
- 2013 European Young Investigator Meeting (EYIM), Paris, France; Mukoviszidose e.V.
- 2012 German Research Foundation (Deutsche Forschungsgemeinschaft, DFG) Winter School Rare Diseases, Göttingen; DFG
- 2010 NACFC, Baltimore, Maryland, USA; Cystic Fibrosis Foundation (CFF)
- 2010 EYIM, Lille, France; Mukoviszidose e.V.

Contribution to Clinical Studies as PI and Co-PI

- 2018-2025 15 Clinical Studies as PI (thereof 1 as Chief Investigator)
- 2018-2025 10 Clinical Studies as Co-PI
- 2009-2017 8 Clinical Studies as Co-PI

Honors and Awards

- 2022 Adalbert Czerny Award for investigation of early CF lung disease via chest MRI, German Society of Pediatrics and Adolescent Medicine (Deutsche Gesellschaft für Kinder- und Jugendmedizin - DGKJ) (10.000€)
- 2019 International Klosterfrau Group Grant for Research of Airway Diseases in Childhood 2019, German Society of Pediatric Pulmonology (GPP) (20.000€)
- 2019 Research Award for Best Clinical Work in Pulmonology, German Society of Pulmonology (DGP) (10.000€)
- 2018 Adolf Windorfer Award, German CF Association (Mukoviszidose e.V.) (5.000€)
- 2018 Young Investigators Award, European Cystic Fibrosis Society (ECFS) (750€)
- 2018 Poster Award, 40. Annual conference of the GPP, Wien, Austria (500€)
- 2015 Poster Award, 37. Annual conference of the GPP, Basel, Switzerland (500€)
- 2014 Poster Award, 36. Annual conference of the GPP, Bremen, Germany (500€)
- 2013 Poster Award, 16. Annual German CF Conference, Würzburg, Germany (250€)
- 2006 Award for best exam in Internal Medicine, University of Freiburg Medical School

Publication list

A. Original articles incl. Case Reports in journals with peer review

1. Thee S, Aleksander P, Lechner L, Posch H, Koegel C, Mall MA, **Stahl M**. Prenatal initiation of elexacaftor/tezacaftor/ivacaftor via carrier mother prevents congenital bilateral absence of vas deferens in a male infant with cystic fibrosis. *J Cyst Fibros*. 2026 Feb 6:S1569-1993(26)00030-5. doi: 10.1016/j.jcf.2026.02.001. Epub ahead of print. PMID: 41654435.
2. Schobert IT, Posch H, Steffen IG, Steinke E, Roehmel J, Mall MA, **Stahl M**, Doellinger F. MRI scoring of pleural findings in cystic fibrosis does not require intravenous contrast media. *Eur Radiol*. 2025 Dec 23. doi: 10.1007/s00330-025-12209-5. Epub ahead of print. PMID: 41436642.
3. Ringwald FG, Wucherpfennig L, Martynova A, Hagen N, Kürschner J, Zhao S, **Stahl M**, Sommerburg O, Mall MA, Graeber SY, Steinke E, Knaup P, Wielpütz MO, Eisenmann U. Automated scoring of airway abnormalities and mucus plugging in chest magnetic resonance imaging of cystic fibrosis using artificial intelligence. *Computational and Structural Biotechnology Journal*. 2025, Volume 28, Pages 442-453, <https://doi.org/10.1016/j.csbj.2025.10.025>.
4. Nussstein H, Urbantat RM, Fentker K, Loewe A, Duerr J, Haji M, Doellinger F, **Stahl M**, Graeber SY, Gradzielski M, Röhmel J, Mertins P, Schaupp L, Mall MA. Changes in Sputum Viscoelastic Properties and Airway Inflammation in Primary Ciliary Dyskinesia are Comparable to Cystic Fibrosis on Elexacaftor/Tezacaftor/Ivacaftor Therapy. *Eur Respir J*. 2025 Sep 18:2500616. doi: 10.1183/13993003.00616-2025. Epub ahead of print. PMID: 40967762.
5. Halle O, Graeber SY, Kontsendorn J, Kessemeier C, Falke JN, Schwabe J, Schütz K, Pallenberg ST, Dalferth R, Grychtol R, Ringshausen FC, **Stahl M**, Thee S, Roehmel JF, Syunyaeva Z, Duerr J, Chung J, Hirtz S, Uselmann T, Kühbandner I, Rückes-Nilges C, Bagheri-Pothoff A, Barth S, Schaub B, Brinkmann F, Weber S, Koningsbruggen-Rietschel SV, Abdo M, Weckmann M, Widder S, Hansen G, Tümmler B, Sommerburg O, Naehrlich L, Mall MA, Dittrich AM. Reduction of systemic inflammation by elexacaftor/tezacaftor/ivacaftor correlates with lung function improvement in cystic fibrosis. *Eur Respir J*. 2025 Sep 18:2500150. doi: 10.1183/13993003.00150-2025. Epub ahead of print. PMID: 40967763.
6. Allomba C, Busack L, Ziegahn N, Pioch CO, Schnorr AN, Fuhlrott BR, Steinke E, Mall MA, **Stahl M**. Feasibility of multiple-breath washout in the clinical setting and prediction of its duration in children and adults with cystic fibrosis. *J Cyst Fibros*. 2025 Sep;24(5):982-990. doi: 10.1016/j.jcf.2025.08.005. Epub 2025 Aug 21. PMID: 40846544.
7. Ziegahn N, Roehmel JF, Pioch CO, Busack LM, Allomba C, Fuhlrott BR, Meinus C, Schnabel O, Yoosefi Moridani M, Thee S, Lau S, Mall MA, **Stahl M**. Multiple-breath washout is more sensitive than spirometry to detect lung function impairment in children and adults with bronchiectasis. *ERJ Open Res*. 2025 Jun 23;11(3):00987-2024. doi: 10.1183/23120541.00987-2024. PMID: 40551806; PMCID: PMC12183715.
8. Aleksander PE, Thee S, Doellinger F, Zagkla S, Mall MA, **Stahl M**. Prenatal Elexacaftor/Tezacaftor/Ivacaftor Treatment Prevents Meconium Ileus, but Not Exocrine Pancreatic Insufficiency and Lung Disease in Infants With Cystic Fibrosis. *Pediatr Pulmonol*. 2025 Jun;60(6):e71168. doi: 10.1002/ppul.71168. PMID: 40525717.
9. Herkner M, Rapp C, Graeber SY, Marx C, Rambuscheck C, Reu-Hofer S, Emiralioglu N, Kiper N, Gilea AI, Notaroberto I, Baruffini E, Temmesfeld-Wollbrück B, Klein C, Wen H, **Stahl M**, Griese M, Gothe F. Multicystic Interstitial Lung Disease Due to a Novel Biallelic C-C Chemokine Receptor Type 2 Variant. *Pediatr Pulmonol* 2025 May;60(5):e71135. doi: 10.1002/ppul.71135. PMID: 40432300; PMCID: PMC12117283.
10. Balázs A, Rubil T, Wong CK, Berger J, Drescher M, Seidel K, **Stahl M**, Graeber SY, Mall MA. The potentiator ivacaftor is essential for pharmacological restoration of F508del-CFTR function and mucociliary clearance in cystic fibrosis. *JCI Insight*. 2025 Apr 22:e187951. doi: 10.1172/jci.insight.187951. Epub ahead of print. PMID: 40261705.
11. Leutz-Schmidt P, Grolig J, Wucherpfennig L, Sommerburg O, Eichinger M, Wege S, Graeber SY, Schenk JP, Alrajab A, Kauczor HU, **Stahl M**, Mall MA, Koeppe A, Nestler

- B, Selzer M, Triphan SMF, Wielpütz MO. Quantitative MRI detects delayed perfusion and impact of bronchial artery dilatation on pulmonary circulation in patients with cystic fibrosis. *Eur Radiol*. 2025 Apr 16. doi: 10.1007/s00330-025-11589-y. Epub ahead of print. PMID: 40240556.
12. Steinke E, Bauman G, Steffen IG, Schobert IT, Thee S, Syunyaeva Z, Roehmel J, Posch H, Fahlenkamp UL, Scale C, Veldhoen S, Bieri O, Wielpütz MO, Mall MA, **Stahl M**, Doellinger F. The established chest MRI score for cystic fibrosis can be applied to contrast agent-free matrix pencil decomposition functional MRI: a multireader analysis. *Front Med (Lausanne)*. 2025 Mar 18;12:1527843. doi: 10.3389/fmed.2025.1527843. PMID: 40171501; PMCID: PMC11958188.
 13. Urbantat RM, Behan L, Wisniewski S, Gardner J, **Stahl M**, Mall MA, Peckham D, Naisbitt DJ, Roehmel JF. Immunogenic adverse events to CFTR modulators - An international survey. *J Cyst Fibros*. 2025 Mar 18:S1569-1993(25)00071-2. doi: 10.1016/j.jcf.2025.03.003. Epub ahead of print. PMID: 40107912.
 14. Hoppe JE, Kasi AS, Pittman JE, Jensen R, Thia LP, Robinson P, Tirakitsoontorn P, Ramsey B, Mall MA, Taylor-Cousar JL, McKone EF, Tullis E, Salinas DB, Zhu J, Chen YC, Rodriguez-Romero V, Sosnay PR, Davies G; **VX21-121-105 Study Group**. Vanzacaftor-tezacaftor-deutivacaftor for children aged 6-11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial. *Lancet Respir Med* 2025 Mar;13(3):244-255. doi: 10.1016/S2213-2600(24)00407-7. Epub 2025 Jan 2. Erratum in: *Lancet Respir Med*. 2025 Mar;13(3):e19. doi: 10.1016/S2213-2600(25)00010-4.
 15. Keating C, Yonker LM, Vermeulen F, Prais D, Linnemann RW, Trimble A, Kotsimbos T, Mermis J, Braun AT, O'Carroll M, Sutharsan S, Ramsey B, Mall MA, Taylor-Cousar JL, McKone EF, Tullis E, Floreth T, Michelson P, Sosnay PR, Nair N, Zahigian R, Martin H, Ahluwalia N, Lam A, Horsley A; **VX20-121-102 Study Group**; **VX20-121-103 Study Group**. Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials. *Lancet Respir Med* 2025 Mar;13(3):256-271. doi: 10.1016/S2213-2600(24)00411-9. Epub 2025 Jan 2. Erratum in: *Lancet Respir Med*. 2025 Mar;13(3):e19. doi: 10.1016/S2213-2600(25)00011-6.
 16. Naehrlich L, Burkhart M; **Registry Working Group of the German CF Registry**. Success of the German Cystic Fibrosis Registry. *Pharmacoepidemiol Drug Saf* 2025 Jan;34(1):e70076. doi: 10.1002/pds.70076.
 17. Wielpütz MO*, **Stahl M***, Triphan SMF, Wucherpfennig L, Leutz-Schmidt P, Gestewitz S, Steinke E, Graeber SY, Kauczor HU, Eichinger M, Puderbach MU, Alrajab A, Schenk JP, Sommerburg O, Mall MA. Longitudinal Magnetic Resonance Imaging of Changes in Lung Morphology and Perfusion in Children with Cystic Fibrosis From Infancy through Adolescence. *Ann Am Thorac Soc*. 2025 Jan;22(1):93-103. doi: 10.1513/AnnalsATS.202404-396OC. PMID: 39255452.
 18. Ramsey KA, Stanojevic S, Chavez L, Johnson N, Bowerman C, Hall GL, Latzin P, O'Neill K, Robinson PD, **Stahl M**, Weiner DJ, Zwitserloot AM, Horsley A; contributing GLI MBW task force members. ERS technical standard: Global Lung Function Initiative reference values for multiple breath washout indices. *Eur Respir J* 2024 Dec 5;64(6):2400524. doi: 10.1183/13993003.00524-2024. PMID: 39326920.
 19. Ringwald FG, Wucherpfennig L, Hagen N, Mücke J, Kaletta S, Eichinger M, **Stahl M**, Triphan SMF, Leutz-Schmidt P, Gestewitz S, Graeber SY, Kauczor HU, Alrajab A, Schenk JP, Sommerburg O, Mall MA, Knaup P, Wielpütz MO, Eisenmann U. Automated lung segmentation on chest MRI in children with cystic fibrosis. *Front Med (Lausanne)* 2024 Nov 12;11:1401473. doi: 10.3389/fmed.2024.1401473.
 20. **Stahl M***, Roehmel J*, Eichinger M, Doellinger F, Naehrlich L, Kopp MV, Dittrich AM, Sommerburg O, Ray P, Maniktala A, Xu T, Conner S, Joshi A, Mascia M, Wielpütz MO, Mall MA. Long-Term Impact of Lumacaftor/Ivacaftor Treatment on Cystic Fibrosis Disease Progression in Children 2-5 Years of Age Homozygous for F508del-CFTR: A Phase 2, Open-Label Clinical Trial. *Ann Am Thorac Soc* 2024 Nov;21(11):1550-1559.

doi: 10.1513/AnnalsATS.202402-201OC.

21. **Stahl M***, Dohna M*, Graeber SY*, Sommerburg O*, Renz DM, Pallenberg ST, Voskrebenezov A, Schütz K, Hansen G, Doellinger F, Steinke E, Thee S, Röhmel J, Barth S, Rückes-Nilges C, Berges J, Hämmerling S, Wielpütz MO, Naehrlich L, Vogel-Claussen J, Tümmler B, Mall MA, Dittrich AM. Impact of elexacaftor/tezacaftor/ivacaftor therapy on lung clearance index and magnetic resonance imaging in children with cystic fibrosis and one or two F508del alleles. *Eur Respir J* 2024 Sep 5;64(3):2400004. doi: 10.1183/13993003.00004-2024.
22. Pioch CO, Ziegahn N, Allomba C, Busack LM, Schnorr AN, Tosolini A, Fuhlrott BR, Zagkla S, Othmer T, Syunyaeva Z, Graeber SY, Yoosefi M, Thee S, Steinke E, Röhmel J, Mall MA, **Stahl M**. Elexacaftor/tezacaftor/ivacaftor improves nasal nitric oxide in patients with cystic fibrosis. *J Cyst Fibros* 2024 Sep;23(5):863-869. doi: 10.1016/j.jcf.2024.03.003.
23. Doellinger F, Bauman G, Roehmel J, **Stahl M**, Posch H, Steffen IG, Pusterla O, Bieri O, Wielpütz MO, Mall MA. Contrast agent-free functional magnetic resonance imaging with matrix pencil decomposition to quantify abnormalities in lung perfusion and ventilation in patients with cystic fibrosis. *Front Med (Lausanne)* 2024 Jun 5;11:1349466. doi: 10.3389/fmed.2024.1349466.
24. Loske J, Völler M, Lukassen S, **Stahl M**, Thürmann L, Seegebarth A, Röhmel J, Wisniewski S, Messingschlager M, Lorenz S, Klages S, Eils R, Lehmann I, Mall MA, Graeber SY, Trump S. Pharmacological Improvement of Cystic Fibrosis Transmembrane Conductance Regulator Function Rescues Airway Epithelial Homeostasis and Host Defense in Children with Cystic Fibrosis. *Am J Respir Crit Care Med* 2024 Jun 1;209(11):1338-1350. doi: 10.1164/rccm.202310-1836OC.
25. Wucherpfennig L, Becker JKZ, Wuennemann F, Eichinger M, Seitz A, Baumann I, **Stahl M**, Graeber SY, Zhao S, Chung J, Schenk JP, Alrajab A, Kauczor HU, Mall MA, Sommerburg O, Wielpütz MO. Elexacaftor/tezacaftor/ivacaftor improves chronic rhinosinusitis detected by magnetic resonance imaging in children with cystic fibrosis on long-term therapy with lumacaftor/ivacaftor. *J Cyst Fibros* 2024 Mar;23(2):234-241. doi: 10.1016/j.jcf.2024.01.004.
26. Wucherpfennig L, Wuennemann F, Eichinger M, Schmitt N, Seitz A, Baumann I, Roehmel JF, **Stahl M**, Hämmerling S, Chung J, Schenk JP, Alrajab A, Kauczor HU, Mall MA, Wielpütz MO, Sommerburg O. Magnetic Resonance Imaging of Pulmonary and Paranasal Sinus Abnormalities in Children with Primary Ciliary Dyskinesia Compared to Children with Cystic Fibrosis. *Ann Am Thorac Soc* 2024 Mar;21(3):438-448. doi: 10.1513/AnnalsATS.202305-453OC.
27. Busack LM, Thee S, Liu Y, Allomba C, Ziegahn N, Tosolini A, Pioch CO, Schnorr AN, Fuhlrott BR, Staudacher O, Völler M, Steinke E, Hanitsch LG, Röhmel J, Wahn V, Krüger R, Mall MA, von Bernuth H, **Stahl M**. Multiple-breath washout to detect lung disease in patients with inborn errors of immunity. *ERJ Open Res* 2024 Mar 11;10(2):01019-2023. doi: 10.1183/23120541.01019-2023.
28. Vijverberg SJH, Kampouras A, Nayir Büyükkşahin H, Makrinioti H, Petrarca L, Schmidt M, Schreck LD, Urbantat RM, Beydon N, Goutaki M, Lavizzari A, Proesmans M, Schramm D, **Stahl M**, Zacharasiewicz A, Moeller A, Pijnenburg MW. ERS International Congress 2023: highlights from the Paediatrics Assembly. *ERJ Open Res* 2024 Feb 26;10(1):00853-2023. doi: 10.1183/23120541.00853-2023.
29. Meißner M, Steinke E, Wielpütz MO, Joachim C, Sommerburg O, Mall MA, **Stahl M**. Impact of Reanalysis of Nitrogen Multiple-Breath Washout on its Relationship with Chest Magnetic Resonance Imaging Findings in Clinically Stable and Pulmonary Exacerbated Children with Cystic Fibrosis. *Klin Padiatr* 2024 Feb;236(2):106-115. English. doi: 10.1055/a-2214-7217.
30. Steinke E, Wielpütz MO, Joachim C, Mall MA, **Stahl M**. Reanalysis of N₂-lung clearance index and the comparison to SF₆-lung clearance index and magnetic resonance imaging. *J Cyst Fibros* 2024 Jan;23(1):150-154. doi: 10.1016/j.jcf.2023.05.006.
31. Rademacher J, Martin L, Theloe A, **Stahl M**, Mall MA, Joean O, Fuge J, Hansen G, Welte T, Schütz K, Ringshausen FC, Dittrich AM. Optimal treatment of the underlying aetiology

- is the most effective antimicrobial stewardship for chronic respiratory disease: a lesson learned from cystic fibrosis. *ERJ Open Res* 2023 Aug 29;9(4):00356-2023. doi: 10.1183/23120541.00356-2023.
32. **Stahl M**, Roehmel J, Eichinger M, Doellinger F, Naehrlich L, Kopp MV, Dittrich AM, Lee C, Sommerburg O, Tian S, Xu T, Wu P, Joshi A, Ray P, Duncan ME, Wielpütz MO, Mall MA. Effects of Lumacaftor/Ivacaftor on Cystic Fibrosis Disease Progression in Children 2 through 5 Years of Age Homozygous for *F508del-CFTR*: A Phase 2 Placebo-controlled Clinical Trial. *Ann Am Thorac Soc* 2023 Aug;20(8):1144-1155. doi: 10.1513/AnnalsATS.202208-684OC.
 33. Wucherpfennig L, Triphan SMF, Wege S, Kauczor HU, Heussel CP, Sommerburg O, **Stahl M**, Mall MA, Eichinger M, Wielpütz MO. Elexacaftor/Tezacaftor/Ivacaftor Improves Bronchial Artery Dilatation Detected by Magnetic Resonance Imaging in Patients with Cystic Fibrosis. *Ann Am Thorac Soc* 2023 Nov;20(11):1595-1604. doi: 10.1513/AnnalsATS.202302-168OC.
 34. Schaupp L, Addante A, Völler M, Fentker K, Kuppe A, Bardua M, Duerr J, Piehler L, Röhmel J, Thee S, Kirchner M, Ziehm M, Lauster D, Haag R, Gradzielski M, **Stahl M**, Mertins P, Boutin S, Graeber SY, Mall MA. Longitudinal effects of elexacaftor/tezacaftor/ivacaftor on sputum viscoelastic properties, airway infection and inflammation in patients with cystic fibrosis. *Eur Respir J* 2023 Aug 3;62(2):2202153. doi: 10.1183/13993003.02153-2022.
 35. Graeber SY, Balázs A, Ziegahn N, Rubil T, Vitzthum C, Piehler L, Drescher M, Seidel K, Rohrbach A, Röhmel J, Thee S, Duerr J, Mall MA, **Stahl M**. Personalized CFTR Modulator Therapy for G85E and N1303K Homozygous Patients with Cystic Fibrosis. *Int J Mol Sci* 2023 Aug 2;24(15):12365. doi: 10.3390/ijms241512365.
 36. Sutharsan S, Dillenhofer S, Welsner M, Stehling F, Brinkmann F, Burkhardt M, Ellemunter H, Dittrich AM, Smaczny C, Eickmeier O, Kappler M, Schwarz C, Sieber S, Naehrig S, Naehrlich L; German CF Registry of the Mukoviszidose e.V. and **participating CF sites**. Impact of elexacaftor/tezacaftor/ivacaftor on lung function, nutritional status, pulmonary exacerbation frequency and sweat chloride in people with cystic fibrosis: real-world evidence from the German CF Registry. *Lancet Reg Health Eur* 2023 Jul 28;32:100690. doi: 10.1016/j.lanpe.2023.100690.
 37. Urbantat RM, Pioch CO, Ziegahn N, Stegemann MS, **Stahl M**, Mall MA, Roehmel JF. Pleuropneumonia caused by *Nocardia cyriacigeorgica* in a 14-year-old girl with primary ciliary dyskinesia. *Pediatr Pulmonol* 2023 Sep;58(9):2656-2658. doi: 10.1002/ppul.26536.
 38. Berges J, Graeber SY, Hämmerling S, Yu Y, Krümpelmann A, **Stahl M**, Hirtz S, Scheuermann H, Mall MA, Sommerburg O. Effects of lumacaftor-ivacaftor therapy on cystic fibrosis transmembrane conductance regulator function in *F508del* homozygous patients with cystic fibrosis aged 2-11 years. *Front Pharmacol* 2023 May 30;14:1188051. doi: 10.3389/fphar.2023.1188051.
 39. Ardura-Garcia C, Kainz K, Mallet MC, Petrarca L, Rodman Berlot J, Slaats M, Streibel C, Vijverberg S, Williams EE, Goutaki M, Gray DM, Lavizzari A, Morty RE, Proesmans M, Schramm D, **Stahl M**, Zacharasiewicz A, Moeller A, Pijnenburg MW. ERS International Congress 2022: highlights from the Paediatrics Assembly. *ERJ Open Res* 2023 May 22;9(3):00653-2022. doi: 10.1183/23120541.00653-2022.
 40. Wucherpfennig L, Wuennemann F, Eichinger M, Schmitt N, Seitz A, Baumann I, **Stahl M**, Graeber SY, Chung J, Schenk JP, Alrajab A, Kauczor HU, Mall MA, Sommerburg O, Wielpütz MO. Longitudinal MRI Detects Onset and Progression of Chronic Rhinosinusitis from Infancy to School Age in Cystic Fibrosis. *Ann Am Thorac Soc* 2023 May;20(5):687-697. doi: 10.1513/AnnalsATS.202209-763OC.
 41. Piehler L, Thalemann R, Lehmann C, Thee S, Röhmel J, Syunyaeva Z, **Stahl M**, Mall MA, Graeber SY. Effects of elexacaftor/tezacaftor/ivacaftor therapy on mental health of patients with cystic fibrosis. *Front Pharmacol* 2023 Apr 21;14:1179208. doi: 10.3389/fphar.2023.1179208.
 42. Wucherpfennig L, Wuennemann F, Eichinger M, Seitz A, Baumann I, **Stahl M**, Graeber SY, Zhao S, Chung J, Schenk JP, Alrajab A, Kauczor HU, Mall MA, Sommerburg O,

- Wielpütz MO. Long-term effects of lumacaftor/ivacaftor on paranasal sinus abnormalities in children with cystic fibrosis detected with magnetic resonance imaging. *Front Pharmacol* 2023 Apr 10;14:1161891. doi: 10.3389/fphar.2023.1161891.
43. Dittrich AS, Dumke M, Kapl F, Schneider P, Wege S, Gräber S, **Stahl M**, Herth FJ, Naehrlich L, Mall MA, Sommerburg O; German CF Registry. Survival-Adjusted FEV1 and BMI Percentiles for Patients with Cystic Fibrosis before the Era of Triple CFTR Modulator Therapy in Germany. *Respiration* 2023;102(5):351-360. doi: 10.1159/000529524.
 44. Leutz-Schmidt P, Optazait DE, Sommerburg O, Eichinger M, Wege S, Steinke E, Graeber SY, Puderbach MU, Schenk JP, Alrajab A, Triphan SMF, Kauczor HU, **Stahl M**, Mall MA, Wielpütz MO. Magnetic resonance imaging detects onset and association with lung disease severity of bronchial artery dilatation in cystic fibrosis. *ERJ Open Res* 2023 Mar 27;9(2):00473-2022. doi: 10.1183/23120541.00473-2022.
 45. Schwarz C, Eschenhagen P, Schmidt H, Hohnstein T, Iwert C, Grehn C, Roehmel J, Steinke E, **Stahl M**, Lozza L, Tikhonova E, Rosati E, Stervbo U, Babel N, Mainz JG, Wisplinghoff H, Ebel F, Jia L-J, Blango MG, Hortschansky P, Brunke S, Hube B, Brakhage A, Kniemeyer O, Scheffold A, Bacher P. Antigen specificity and cross-reactivity drive functionally diverse T cell responses against *Aspergillus fumigatus* in cystic fibrosis patients. *J Clin Invest* 2023 Mar 1;133(5):e161593. doi: 10.1172/JCI161593.
 46. Steinke E, Sommerburg O, Graeber SY, Joachim C, Labitzke C, Nissen G, Ricklefs I, Rudolf I, Kopp MV, Dittrich AM, Mall MA, **Stahl M**. TRACK-CF prospective cohort study: Understanding early cystic fibrosis lung disease. *Front Med (Lausanne)*. 2023 Jan 6;9:1034290. doi: 10.3389/fmed.2022.1034290.
 47. Roehmel JF, Doerfler FJ, Koerner-Rettberg C, Brinkmann F, Schlegtendal A, Wetzke M, Rudolf I, Helms S, Große-Onnebrink J, Yu Y, Nuesslein T, Wojsyk-Banaszak I, Becker S, Eickmeier O, Sommerburg O, Omran H, **Stahl M**, Mall MA. Comparison of the Lung Clearance Index in Preschool Children With Primary Ciliary Dyskinesia and Cystic Fibrosis. *Chest* 2022 Sep;162(3):534-542. doi: 10.1016/j.chest.2022.02.052.
 48. Graeber SY*, Renz DM*, **Stahl M***, Pallenberg ST*, Sommerburg O, Naehrlich L, Berges J, Dohna M, Ringshausen FC, Doellinger F, Vitzthum C, Röhmel J, Allomba C, Hämmerling S, Barth S, Rückes-Nilges C, Wielpütz MO, Hansen G, Vogel-Claussen J, Tümmler B, Mall MA, Dittrich AM. Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on Lung Clearance Index and Magnetic Resonance Imaging in Patients with Cystic Fibrosis and One or Two F508del Alleles. *Am J Respir Crit Care Med* 2022 Aug 1;206(3):311-320. doi: 10.1164/rccm.202201-0219OC.
 49. Frey DL, Bridson C, Dittrich S, Graeber SY, **Stahl M**, Wege S, Herth F, Sommerburg O, Schultz C, Dalpke A, Mall MA, Boutin S. Changes in Microbiome Dominance Are Associated With Declining Lung Function and Fluctuating Inflammation in People With Cystic Fibrosis. *Front Microbiol* 2022 May 13;13:885822. doi: 10.3389/fmicb.2022.885822. eCollection 2022.
 50. Sommerburg O, **Stahl M**, Hämmerling S, Gramer G, Muckenthaler MU, Okun J, Kohlmüller D, Happich M, Kulozik AE, Mall MA, Hoffmann GF. Final results of the southwest German pilot study on cystic fibrosis newborn screening - Evaluation of an IRT/PAP protocol with IRT-dependent safety net: Results of the Southwest German CFNBS pilot study. *J Cyst Fibros* 2022 May;21(3):422-433. doi: 10.1016/j.jcf.2021.10.007.
 51. Griese M, Panagiotou P, Manali ED, **Stahl M**, Schwerk N, Costa V, Douros K, Kallieri M, Urbantat RM, von Bernuth H, Kolilekas L, Morais L, Ramos A, Landwehr K, Knoflach K, Gothe F, Reiter K, Papaevangelou V, Kaditis AG, Kanaka-Gantenbein C, Papiris SA. Autoimmune pulmonary alveolar proteinosis in children. *ERJ Open Res* 2022 Mar 21;8(1):00701-2021. doi: 10.1183/23120541.00701-2021. eCollection 2022 Jan.
 52. Graeber SY, Vitzthum C, Pallenberg ST, Naehrlich L, **Stahl M**, Rohrbach A, Drescher M, Minso R, Ringshausen FC, Rueckes-Nilges C, Klajda J, Berges J, Yu Y, Scheuermann H, Hirtz S, Sommerburg O, Dittrich AM, Tümmler B, Mall MA. Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on CFTR Function in Patients with Cystic Fibrosis and One or Two F508del Alleles. *Am J Respir Crit Care Med* 2022 Mar 1;205(5):540-549. doi: 10.1164/rccm.202110-2249OC.

53. Thee S, Busack LM, Mall MA, **Stahl M**. Impact of lockdown during the COVID-19 pandemic on health status in patients with cystic fibrosis: a mono-centre observational study. *ERJ Open Res* 2022 Mar 14;8(1):00588-2021. doi: 10.1183/23120541.00588-2021. eCollection 2022 Jan.
54. Metzger MI, Graeber SY, **Stahl M**, Sommerburg O, Mall MA, Dalpke AH, Boutin S. A Volatile and Dynamic Longitudinal Microbiome Is Associated With Less Reduction in Lung Function in Adolescents With Cystic Fibrosis. *Front Cell Infect Microbiol* 2021 Dec 6;11:763121. doi: 10.3389/fcimb.2021.763121. eCollection 2021.
55. **Stahl M***, Steinke E*, Graeber SY, Joachim C, Seitz C, Kauczor HU, Eichinger M, Hämmerling S, Sommerburg O, Wielpütz MO, Mall MA. Magnetic Resonance Imaging Detects Progression of Lung Disease and Impact of Newborn Screening in Preschool Children with Cystic Fibrosis. *Am J Respir Crit Care Med* 2021 Oct 15;204(8):943-953. doi: 10.1164/rccm.202102-0278OC.
56. Frey DL, Boutin S, Dittrich SA, Graeber SY, **Stahl M**, Wege S, Herth FJF, Sommerburg O, Schultz C, Mall MA, Dalpke AH. Relationship between airway dysbiosis, inflammation and lung function in adults with cystic fibrosis. *J Cyst Fibros* 2021 Sep;20(5):754-760. doi: 10.1016/j.jcf.2020.12.022.
57. Graeber SY, Boutin S, Wielpütz MO, Joachim C, Frey DL, Wege S, Sommerburg O, Kauczor HU, **Stahl M**, Dalpke AH, Mall MA. Effects of Lumacaftor-Ivacaftor on Lung Clearance Index, Magnetic Resonance Imaging and Airway Microbiome in Phe508del Homozygous Patients with Cystic Fibrosis. *Ann Am Thorac Soc* 2021 Jun;18(6):971-980. doi: 10.1513/AnnalsATS.202008-1054OC.
58. Thee S, **Stahl M**, Fischer R, Sutharsan S, Ballmann M, Müller A, Lorenz D, Urbanski-Rini D, Püschner F, Amelung VE, Fuchs C, Mall MA. A multi-centre, randomized, controlled trial on coaching and telemonitoring in patients with cystic fibrosis: conneCT CF. *BMC Pulm Med*. 2021 Apr 21;21(1):131. doi: 10.1186/s12890-021-01500-y.
59. Sommerburg O, Hämmerling S, Schneider SP, Okun J, Langhans CD, Leutz-Schmidt P, Wielpütz MO, Siems W, Gräber SY, Mall MA, **Stahl M**. CFTR Modulator Therapy with Lumacaftor/Ivacaftor Alters Plasma Concentrations of Lipid-Soluble Vitamins A and E in Patients with Cystic Fibrosis. *Antioxidants (Basel)*. 2021 Mar 19;10(3):483. doi: 10.3390/antiox10030483.
60. **Stahl M**, Joachim C, Kirsch I, Uselmann T, Yu Y, Alfeis N, Berger C, Minso R, Rudolf I, Stolpe C, Bovermann X, Liboschik L, Steinmetz A, Tennhardt D, Dörfler F, Röhmel J, Unorji-Frank K, Rückes-Nilges C, von Stoutz B, Naehrlich L, Kopp MV, Dittrich AM, Sommerburg O, Mall MA. Multicentre feasibility of multiple-breath washout in preschool children with cystic fibrosis and other lung diseases. *ERJ Open Res* 2020;6:00408-2020. doi: 10.1183/23120541.00408-2020.
61. Triphan SMF, **Stahl M**, Jobst BJ, Sommerburg O, Kauczor HU, Schenk JP, Alrajab A, Eichinger M, Mall MA, Wielpütz MO. Echo Time-Dependence of Observed Lung T1 in Patients With Cystic Fibrosis and Correlation With Clinical Metrics. *J Magn Reson Imaging* 2020 Dec;52(6):1645-1654. doi: 10.1002/jmri.27271.
62. Lenz D*, **Stahl M***, Seidl E*, Schöndorf D, Brennenstuhl H, Gesenhues F, Heinzmann T, Longerich T, Mendes MI, Prokisch H, Salomons GS, Schön C, Smith DEC, Sommerburg O, Wagner M, Westhoff JH, Reiter K, Stauffer C, Griese M. Rescue of respiratory failure in pulmonary alveolar proteinosis due to pathogenic MARS1 variants. *Pediatr Pulmonol* 2020 Nov;55(11):3057-3066. doi: 10.1002/ppul.25031.
63. Sommerburg O, Wielpütz MO, Trame JP, Wuennemann F, Optazait E, **Stahl M**, Puderbach MU, Kopp-Schneider A, Fritzsching E, Kauczor HU, Baumann I, Mall MA, Eichinger M. Magnetic resonance imaging detects chronic rhinosinusitis in infants and preschool children with cystic fibrosis. *Ann Am Thorac Soc* 2020;17(6):714-723. doi: 10.1513/AnnalsATS.201910-777OC.
64. Konietzke P, Mueller J, Wuennemann F, Wagner WL, Schenk JP, Alrajab A, Kauczor HU, **Stahl M**, Mall MA, Wielpütz MO, Sommerburg O. The value of chest magnetic resonance imaging compared to chest radiographs with and without additional lung ultrasound in children with complicated pneumonia. *PLoS One* 2020;19;15(3):e0230252. doi: 10.1371/journal.pone.0230252.

65. Anagnostopoulou P, Latzin P, Jensen R, **Stahl M**, Harper A, Yammine S, Usemann J, Foong RE, Spycher B, Hall GL, Singer F, Stanojevic S, Mall M, Ratjen F, Ramsey KA. Normative data for multiple breath washout outcomes in school-aged Caucasian children. *Eur Respir J* 2020;3;55(4):1901302. doi: 10.1183/13993003.01302-2019.
66. **Stahl M**, Wielpütz MO, Ricklefs I, Dopfer C, Barth S, Schlegtendal A, Graeber SY, Sommerburg O, Diekmann G, Hüsing J, Koerner-Rettberg C, Nährlich L, Dittrich AM, Kopp MV, Mall MA. Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS): A randomized, double-blind, controlled study. *Am J Respir Crit Care Med* 2019;199(10):1238-1248. doi: 10.1164/rccm.201807-1203OC.
67. **Stahl M**, Joachim C, Wielpütz MO, Mall MA. Comparison of lung clearance index determined by washout of N₂ and SF₆ in infants and preschool children with cystic fibrosis. *J Cyst Fibros* 2019;18(3):399-406. doi: 10.1016/j.jcf.2018.11.001.
68. Wielpütz MO, von Stackelberg O, **Stahl M**, Jobst BJ, Eichinger M, Puderbach MU, Nährlich L, Barth S, Schneider C, Kopp MV, Ricklefs I, Buchholz M, Tümmler B, Dopfer C, Vogel-Claussen J, Kauczor HU, Mall MA. Multicentre standardisation of chest MRI as radiation-free outcome measure of lung disease in young children with cystic fibrosis. *J Cyst Fibros* 2018;17:518-527. doi: 10.1016/j.jcf.2018.05.003.
69. Boutin S, Weitnauer M, Hassel S, Graeber SY, **Stahl M**, Dittrich AS, Mall MA, Dalpke AH. One time quantitative PCR detection of *Pseudomonas aeruginosa* to discriminate intermittent from chronic infection in cystic fibrosis. *J Cyst Fibros* 2018;17:348-355. doi: 10.1016/j.jcf.2017.12.007.
70. Leutz-Schmidt P, **Stahl M**, Sommerburg O, Eichinger M, Puderbach MU, Schenk JP, Alrajab A, Triphan SMF, Kauczor HU, Mall MA, Wielpütz MO. Non-contrast enhanced magnetic resonance imaging detects mosaic signal intensity in early cystic fibrosis lung disease. *Eur J Radiol* 2018;101:178-183. doi: 10.1016/j.ejrad.2018.02.023.
71. **Stahl M**, Graeber SY, Joachim C, Barth S, Ricklefs I, Diekmann G, Kopp MV, Nährlich L, Mall MA. Three-center feasibility of lung clearance index in infants and preschool children with cystic fibrosis and other lung diseases. *J Cyst Fibros* 2018;17:249-255. doi: 10.1016/j.jcf.2017.08.001.
72. **Stahl M**, Holfelder C, Kneppo C, Kieser M, Kasperk C, Schoenau E, Sommerburg O, Tonshoff B. Multiple prevalent fractures in relation to macroscopic bone architecture in patients with cystic fibrosis. *J Cyst Fibros* 2018;17:114-120. doi: 10.1016/j.jcf.2016.06.004.
73. Boutin S, Depner M, **Stahl M**, Graeber SY, Dittrich SA, Legatzki A, von Mutius E, Mall M, Dalpke AH. Comparison of Oropharyngeal Microbiota from Children with Asthma and Cystic Fibrosis. *Mediators Inflamm* 2017. doi: 10.1155/2017/5047403.
74. Boutin S, Graeber SY, **Stahl M**, Dittrich AS, Mall MA, Dalpke AH. Chronic but not intermittent infection with *Pseudomonas aeruginosa* is associated with global changes of the lung microbiome in cystic fibrosis. *Eur Respir J* 2017;50:1701086. doi: 10.1183/13993003.01086-2017.
75. Sommerburg O, **Stahl M**, Hammermann J, Okun JG, Kulozik A, Hoffmann G, Mall M. [Newborn Screening on Cystic Fibrosis in Germany: Comparison of the new Screening Protocol with an Alternative Protocol]. *Klin Padiatr* 2017;229:59-66. doi: 10.1055/s-0042-124187.
76. **Stahl M**, Wielpütz MO, Graeber SY, Joachim C, Sommerburg O, Kauczor HU, Puderbach M, Eichinger M, Mall MA. Comparison of Lung Clearance Index and Magnetic Resonance Imaging for Assessment of Lung Disease in Children with Cystic Fibrosis. *Am J Respir Crit Care Med* 2017;195:349-359. doi: 10.1164/rccm.201604-0893OC.
77. Sommerburg O, Hammermann J, Lindner M, **Stahl M**, Muckenthaler M, Kohlmüller D, Happich M, Kulozik AE, Stopsack M, Gahr M, Hoffmann GF, Mall MA. Five years of experience with biochemical cystic fibrosis newborn screening based on IRT/PAP in Germany. *Pediatr Pulmonol* 2015;50:655-664. doi: 10.1002/ppul.23190.
78. Hector A, Schafer H, Poschel S, Fischer A, Fritzsching B, Ralhan A, Carevic M, Oz H, Zundel S, Hogardt M, Bakele M, Rieber N, Riethmüller J, Graepler-Mainka U, **Stahl M**, Bender A, Frick JS, Mall M, Hartl D. Regulatory T-cell impairment in cystic fibrosis patients with chronic *pseudomonas* infection. *Am J Respir Crit Care Med* 2015;191:914-

923. doi: 10.1164/rccm.201407-1381OC.
79. Boutin S, Graeber SY, Weitnauer M, Panitz J, **Stahl M**, Clausznitzer D, Kaderali L, Einarsson G, Tunney MM, Elborn JS, Mall MA, Dalpke AH. Comparison of microbiomes from different niches of upper and lower airways in children and adolescents with cystic fibrosis. *PLoS One* 2015;10:e0116029. doi: 10.1371/journal.pone.0116029.
 80. Wielpütz MO, Puderbach M, Kopp-Schneider A, **Stahl M**, Fritzsching E, Sommerburg O, Ley S, Sumkauskaitė M, Biederer J, Kauczor HU, Eichinger M, Mall MA. Magnetic resonance imaging detects changes in structure and perfusion, and response to therapy in early cystic fibrosis lung disease. *Am J Respir Crit Care Med* 2014;189:956-965. doi: 10.1164/rccm.201309-1659OC.
 81. **Stahl M**, Joachim C, Blessing K, Hämmerling S, Sommerburg O, Latzin P, Mall MA. Multiple breath washout is feasible in the clinical setting and detects abnormal lung function in infants and young children with cystic fibrosis. *Respiration* 2014;87:357-363. doi: 10.1159/000357075.
 82. Sommerburg O, Krulisova V, Hammermann J, Lindner M, **Stahl M**, Muckenthaler M, Kohlmüller D, Happich M, Kulozik AE, Votava F, Balascakova M, Skalicka V, Stopsack M, Gahr M, Macek M, Jr., Mall MA, Hoffmann GF. Comparison of different IRT-PAP protocols to screen newborns for cystic fibrosis in three central European populations. *J Cyst Fibros* 2014;13:15-23. doi: 10.1016/j.jcf.2013.06.003.
 83. **Stahl M**, Schupp J, Jäger B, Schmid M, Zissel G, Müller-Quernheim J, Prasse A. Lung collagens perpetuate pulmonary fibrosis via CD204 and M2 macrophage activation. *PLoS One* 2013;8:e81382. doi: 10.1371/journal.pone.0081382.
 84. Beck BB, Baasner A, Buescher A, Habbig S, Reintjes N, Kemper MJ, Sikora P, Mache C, Pohl M, **Stahl M**, Toenshoff B, Pape L, Fehrenbach H, Jacob DE, Grohe B, Wolf MT, Nürnberg G, Yigit G, Salido EC, Hoppe B. Novel findings in patients with primary hyperoxaluria type III and implications for advanced molecular testing strategies. *Eur J Hum Genet* 2013;21:162-172. doi: 10.1038/ejhg.2012.139.
 85. Prasse A, **Stahl M**, Schulz G, Kayser G, Wang L, Ask K, Yalcintepe J, Kirschbaum A, Bargagli E, Zissel G, Kolb M, Müller-Quernheim J, Weiss JM, Renkl AC. Essential role of osteopontin in smoking-related interstitial lung diseases. *Am J Pathol* 2009;174:1683-1691. doi: 10.2353/ajpath.2009.080689.
 86. Prasse A, Germann M, Pechkovsky DV, Markert A, Verres T, **Stahl M**, Melchers I, Luttmann W, Müller-Quernheim J, Zissel G. IL-10-producing monocytes differentiate to alternatively activated macrophages and are increased in atopic patients. *J Allergy Clin Immunol* 2007;119:464-471. doi: 10.1016/j.jaci.2006.09.030.

B. Invited reviews in journals with peer review

1. Lee T, Hill K, Caudri D, Ciet P, Davies G, Davies JC, Dittrich AM, Lindblad A, McNally P, Reix P, Saunders C, Sermet-Gaudelus I, **Stahl M**, Tiddens HAWM, Janssens HM. Pulmonary endpoints in clinical trials for children with cystic fibrosis under two years of age. *J Cyst Fibros* 2025 Jul;24(4):669-683. doi: 10.1016/j.jcf.2025.06.003. Epub 2025 Jul 4. PMID: 40615279.
2. Fayon M, Hill K, Waldron M, Messori B, Riberi L, Svedberg M, Lammertyn E, Fustik S, Gramegna A, **Stahl M**, Kerpel-Fronius A, Balbi M, Ciet P, Chassagnon G, Ferrero C, Burgel PR, Sutharsan S, Opitz M, Andrinopoulou ER, Dournes G, Maher M, Duckers J, Tiddens H, Sermet I. Guidance for chest-CT in children and adults with cystic fibrosis: A European perspective. *Respir Med*. 2025 May;241:108076. doi: 10.1016/j.rmed.2025.108076. Epub 2025 Apr 4. PMID: 40189162.
3. Syunyaeva Z, Mall MA, **Stahl M**. Mukoviszidose im Kindes- und im Erwachsenenalter [Cystic fibrosis in childhood and adulthood]. *Inn Med (Heidelb)* 2024 Jun;65(6):538-544. German. doi: 10.1007/s00108-024-01717-z.
4. Kisseleff J, **Stahl M**, Farr A, Watson P, Cruz J. What to expect of the first ERS/ECFS Adult Cystic Fibrosis Conference. *Breathe (Sheff)*. 2023 Sep;19(3):230152. doi: 10.1183/20734735.0152-2023.
5. **Stahl M**, Steinke E, Mall MA. Quantification of Phenotypic Variability of Lung Disease in Children with Cystic Fibrosis. *Genes* 2021 May 25;12(6):803. doi:

10.3390/genes12060803.

6. **Stahl M.** [Clinical presentation of lung disease in cystic fibrosis]. *Radiologe* 2020;60(9):774-780. doi: 10.1007/s00117-020-00728-9.
7. Leutz-Schmidt P, Eichinger M, Sommerburg O, **Stahl M**, Triphan SMF, Gehlen S, Kauczor HU, Puderbach MU, Mall MA, Wielpütz MO. [Magnetic resonance imaging of the lungs in cystic fibrosis]. *Radiologe* 2020;60(9):813-822. doi: 10.1007/s00117-020-00723-0.
8. Bischoff A, Weinheimer O, Eichinger M, **Stahl M**, Sommerburg O, Kauczor HU, Mall MA, Wielpütz MO. [Cystic fibrosis and computed tomography of the lungs]. *Radiologe* 2020;60(9):791-801. doi: 10.1007/s00117-020-00713-2.
9. Leutz-Schmidt P, Eichinger M, **Stahl M**, Sommerburg O, Biederer J, Kauczor HU, Puderbach MU, Mall MA, Wielpütz MO. Ten years of chest MRI for patients with cystic fibrosis: Translation from the bench to clinical routine. *Radiologe* 2019;59:10-20. doi: 10.1007/s00117-019-0553-2.
10. Mall MA, **Stahl M**, Graeber SY, Sommerburg O, Kauczor HU, Wielpütz MO. Early detection and sensitive monitoring of CF lung disease: Prospects of improved and safer imaging. *Pediatr Pulmonol* 2016;51:S49-S60. doi: 10.1002/ppul.23537.
11. Wielpütz MO, Eichinger M, Biederer J, Wege S, **Stahl M**, Sommerburg O, Mall MA, Kauczor HU, Puderbach M. Imaging of Cystic Fibrosis Lung Disease and Clinical Interpretation. *Rofo* 2016;188:834-845. doi: 10.1055/s-0042-104936.
12. Mall MA, Graeber SY, **Stahl M**, Zhou-Suckow Z. Early cystic fibrosis lung disease: Role of airway surface dehydration and lessons from preventive rehydration therapies in mice. *Int J Biochem Cell Biol* 2014;52:174-179. doi: 10.1016/j.biocel.2014.02.006.

C. Letters to the Editor

1. **Stahl M**, Röhmel J, Wielpütz MO, Mall MA. Reply to Martin and Grasemann: Is There a Role for Lumacaftor/Ivacaftor in Young Children with Cystic Fibrosis? *Ann Am Thorac Soc*. 2025 Mar;22(3):469-470. doi: 10.1513/AnnalsATS.202411-1237LE.
2. Piehler L, Thalemann R, Lehmann C, **Stahl M**, Mall MA, Graeber SY. Depression Symptoms in Patients with Cystic Fibrosis Fluctuate at Baseline and Improve with Elexacaftor/Tezacaftor/Ivacaftor Therapy. *Am J Respir Crit Care Med* 2024 Aug 1;210(3):365-367. doi: 10.1164/rccm.202404-0787LE.
3. Othmer JT, Hoffmann L, **Stahl M**. Valsalva Purpura After Gastroscopy. *Dtsch Arztebl Int* 2024 May 31;121(11):362. doi: 10.3238/arztebl.m2023.0252.
4. Kentgens AC, Latzin P, Anagnostopoulou P, Jensen R, **Stahl M**, Harper A, Yammine S, Foong RE, Hall GL, Singer F, Stanojevic S, Mall MA, Ratjen F, Ramsey KA. Normative multiple breath washout data in school-aged children corrected for sensor error. *Eur Respir J* 2022 Aug 18;60(2):2102398. doi: 10.1183/13993003.02398-2021.
5. **Stahl M**, Steinke E, Wielpütz MO, Mall MA; all authors of "Magnetic Resonance Imaging Detects Progression of Lung Disease and Impact of Newborn Screening in Preschool Children with Cystic Fibrosis". Reply to: Contrast Enhanced Magnetic Resonance Imaging Does Not Detect a Progression in Lung Morphological Score in Preschool Children with Cystic Fibrosis. *Am J Respir Crit Care Med* 2022 Jan 1;205(1):134-136. doi: 10.1164/rccm.202109-2050LE.
6. **Stahl M**, Joachim C, Wielpütz MO, Mall MA. Authors' response: Letter to the Editor 'Comparison of lung clearance index determined by washout of N₂ and SF₆ in infants and preschool children with cystic fibrosis'. *J Cyst Fibros* 2019;18(3):e28-e29. doi: 10.1016/j.jcf.2019.01.016.
7. **Stahl M**, Wielpütz MO, Kauczor HU, Mall MA, all authors. Reply to Verbanck and Vanderhelst: The Respective Roles of Lung Clearance Index and Magnetic Resonance Imaging in the Clinical Management of Patients with Cystic Fibrosis. *Am J Respir Crit Care Med* 2018;197:410-411. doi: 10.1164/rccm.201707-1367LE.

D. Editorials

1. Steinke E, **Stahl M**. Sustained Improvement of Cystic Fibrosis Lung Disease following Initiation of Elexacaftor/Tezacaftor/Ivacaftor Therapy: Lessons from Real-World Studies.

Am J Respir Crit Care Med. 2023 Nov 1;208(9):911-913. doi: 10.1164/rccm.202309-1646ED.

2. **Stahl M.** Sensitive markers to detect progression of lung disease in children with cystic fibrosis. *Eur Respir J* 2021 Jul 8;58(1):2100236. doi: 10.1183/13993003.00236-2021.

E. Book chapters

1. Shteinberg M, **Stahl M.** Other Cystic Fibrosis-Related Diseases and Complications. In: Hodson and Geddes' Cystic Fibrosis, Chapter 38. 5th Edition, 2023. Editors: Andrew Bush, Margarida D. Amaral, Jane C. Davies, Nicholas J. Simmonds, Jennifer L. Taylor-Cousar, Sarath C. Ranganathan. CRC Press, Boca Raton, USA. <https://doi.org/10.1201/9781003262763>
2. Tiddens HAWM, van Straten M, **Stahl M,** Ciet P. Imaging of Cystic Fibrosis Lung Disease. In: Hodson and Geddes' Cystic Fibrosis, Chapter 46. 5th Edition, 2023. Editors: Andrew Bush, Margarida D. Amaral, Jane C. Davies, Nicholas J. Simmonds, Jennifer L. Taylor-Cousar, Sarath C. Ranganathan. CRC Press, Boca Raton, USA. <https://doi.org/10.1201/9781003262763>
3. **Stahl M,** Wielpütz, MO. Moderne Bildgebung der CF-Lunge. In: CF-Manual, Chapter 25. 3rd Edition, 2022. Editors: Manfred Ballmann, Christina Smaczny, Sivagurunathan Sutharsan, Anna-Maria Dittrich. Georg Thieme Verlag, Stuttgart.
4. **Stahl M.** Lung function. In: Mutation-specific therapies in cystic fibrosis, Chapter 3 Endpoints of phase II and III trials with CFTR modulators. 2nd Edition, 2022. Editor: Burkard Tümmler. UNI-MED Verlag AG, Bremen.

*shared first or last authorship

Berlin, February 18th 2026

M. Stahl